Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Vascular Surgery

  Free Subscription


Articles published in Am Heart J

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    January 2018
  1. AFANA M, Gurm HS, Seth M, Frazier KM, et al
    Primary percutaneous coronary intervention at centers with and without on-site surgical support: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Am Heart J. 2018;195:99-107.
    PubMed     Text format     Abstract available


  2. EGBE A, Khan AR, Khan SF, Anavekar NS, et al
    Role of Doppler echocardiography for cardiac output assessment in Fontan patients.
    Am Heart J. 2018;195:91-98.
    PubMed     Text format     Abstract available


  3. LIU E, Hsueh L, Kim H, Vidovich MI, et al
    Global geographical variation in patient characteristics in percutaneous coronary intervention clinical trials: A systematic review and meta-analysis.
    Am Heart J. 2018;195:39-49.
    PubMed     Text format     Abstract available


    December 2017
  4. EGBE AC, Huntley GD, Connolly HM, Ammash NM, et al
    Outcomes of cardiac pacing in adult patients after a Fontan operation.
    Am Heart J. 2017;194:92-98.
    PubMed     Text format     Abstract available


  5. ILIESCU CA, Cilingiroglu M, Giza DE, Rosales O, et al
    "Bringing on the light" in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry).
    Am Heart J. 2017;194:83-91.
    PubMed     Text format     Abstract available


  6. QADERDAN K, Vos GA, McAndrew T, Steg PG, et al
    Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials.
    Am Heart J. 2017;194:73-82.
    PubMed     Text format     Abstract available


  7. INOHARA T, Numasawa Y, Higashi T, Ueda I, et al
    Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications.
    Am Heart J. 2017;194:61-72.
    PubMed     Text format     Abstract available


    November 2017
  8. LEE PH, Lee JY, Lee CW, Han S, et al
    Long-term outcomes of bypass grafting versus drug-eluting stenting for left main coronary artery disease: Results from the IRIS-MAIN registry.
    Am Heart J. 2017;193:76-83.
    PubMed     Text format     Abstract available


    October 2017
  9. DEHGHANI P, Lavoie A, Lavi S, Crawford JJ, et al
    Effects of ticagrelor versus clopidogrel on platelet function in fibrinolytic-treated STEMI patients undergoing early PCI.
    Am Heart J. 2017;192:105-112.
    PubMed     Text format     Abstract available


    September 2017
  10. GUDNADOTTIR GS, Andersen K, Thrainsdottir IS, James SK, et al
    Gender differences in coronary angiography, subsequent interventions, and outcomes among patients with acute coronary syndromes.
    Am Heart J. 2017;191:65-74.
    PubMed     Text format     Abstract available


  11. WEI J, Mehta PK, Grey E, Garberich RF, et al
    Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol.
    Am Heart J. 2017;191:30-36.
    PubMed     Text format     Abstract available


    August 2017
  12. PROIETTI M, Airaksinen KEJ, Rubboli A, Schlitt A, et al
    Time in therapeutic range and major adverse outcomes in atrial fibrillation patients undergoing percutaneous coronary intervention: The Atrial Fibrillation Undergoing Coronary Artery Stenting (AFCAS) registry.
    Am Heart J. 2017;190:86-93.
    PubMed     Text format     Abstract available


  13. PALMERINI T, Serruys P, Kappetein AP, Genereux P, et al
    Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients.
    Am Heart J. 2017;190:54-63.
    PubMed     Text format     Abstract available


    July 2017
  14. FROBERT O, Gotberg M, Angeras O, Jonasson L, et al
    Design and rationale for the Influenza vaccination After Myocardial Infarction (IAMI) trial. A registry-based randomized clinical trial.
    Am Heart J. 2017;189:94-102.
    PubMed     Text format     Abstract available


  15. OHUCHI H, Miyazaki A, Negishi J, Hayama Y, et al
    Hemodynamic determinants of mortality after Fontan operation.
    Am Heart J. 2017;189:9-18.
    PubMed     Text format     Abstract available


  16. ARIOTTI S, van Leeuwen M, Brugaletta S, Leonardi S, et al
    Rationale and design of the Hunting for the off-target propertIes of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial.
    Am Heart J. 2017;189:128-136.
    PubMed     Text format     Abstract available


    June 2017
  17. BABER U, Sartori S, Aquino M, Kini A, et al
    Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study.
    Am Heart J. 2017;188:73-81.
    PubMed     Text format     Abstract available


  18. WIDMER RJ, Allison TG, Lennon R, Lopez-Jimenez F, et al
    Digital health intervention during cardiac rehabilitation: A randomized controlled trial.
    Am Heart J. 2017;188:65-72.
    PubMed     Text format     Abstract available


  19. GOLDBERG DJ, Zak V, Goldstein BH, Chen S, et al
    Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation.
    Am Heart J. 2017;188:42-52.
    PubMed     Text format     Abstract available


  20. SELKER HP, Udelson JE, Ruthazer R, D'Agostino RB, et al
    Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials.
    Am Heart J. 2017;188:18-25.
    PubMed     Text format     Abstract available


  21. ABNOUSI F, Sundaram V, Yong CM, Prats J, et al
    Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial.
    Am Heart J. 2017;188:147-155.
    PubMed     Text format     Abstract available


  22. MELINA G, Angeloni E, Refice S, Monti F, et al
    Clinical SYNTAX score predicts outcomes of patients undergoing coronary artery bypass grafting.
    Am Heart J. 2017;188:118-126.
    PubMed     Text format     Abstract available


  23. KEDHI E, Fabris E, van der Ent M, Kennedy MW, et al
    A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the "DAPT-STEMI trial".
    Am Heart J. 2017;188:11-17.
    PubMed     Text format     Abstract available


    May 2017
  24. FENDER EA, Liang JJ, Sio TT, Stulak JM, et al
    Percutaneous revascularization in patients treated with thoracic radiation for cancer.
    Am Heart J. 2017;187:98-103.
    PubMed     Text format     Abstract available


  25. FINESCHI M, Verna E, Mezzapelle G, Bartolini D, et al
    Assessing MICRO-vascular resistances via IMR to predict outcome in STEMI patients with multivessel disease undergoing primary PCI (AMICRO): Rationale and design of a prospective multicenter clinical trial.
    Am Heart J. 2017;187:37-44.
    PubMed     Text format     Abstract available


  26. BAGAI A, Peterson ED, McCoy LA, Effron MB, et al
    Association of measured platelet reactivity with changes in P2Y12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of
    Am Heart J. 2017;187:19-28.
    PubMed     Text format     Abstract available


  27. LEMMERT ME, Oldroyd K, Barragan P, Lesiak M, et al
    Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicent
    Am Heart J. 2017;187:104-111.
    PubMed     Text format     Abstract available


  28. SCIAHBASI A, Rigattieri S, Sarandrea A, Cera M, et al
    Determinants of operator radiation exposure during percutaneous coronary procedures.
    Am Heart J. 2017;187:10-18.
    PubMed     Text format     Abstract available


    April 2017
  29. SMITS PC, Assaf A, Richardt G, Omerovic E, et al
    Design and rationale of the COMPARE-ACUTE trial: Fractional flow reserve-guided primary multivessel percutaneous coronary intervention to improve guideline indexed actual standard of care for treatment of ST-elevation myocardial infarction in patients
    Am Heart J. 2017;186:21-28.
    PubMed     Text format     Abstract available


  30. EGBE AC, Connolly HM, Khan AR, Niaz T, et al
    Outcomes in adult Fontan patients with atrial tachyarrhythmias.
    Am Heart J. 2017;186:12-20.
    PubMed     Text format     Abstract available


  31. HANNAN EL, Zhong Y, Jacobs AK, Ling FSK, et al
    Incomplete revascularization for percutaneous coronary interventions: Variation among operators, and association with operator and hospital characteristics.
    Am Heart J. 2017;186:118-126.
    PubMed     Text format     Abstract available


    March 2017
  32. BAVISHI C, Sardar P, Chatterjee S, Khan AR, et al
    Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: Meta-analysis of randomized trials.
    Am Heart J. 2017;185:26-34.
    PubMed     Text format     Abstract available


  33. LEE H, Koo BK, Park KW, Shin ES, et al
    A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary arte
    Am Heart J. 2017;185:17-25.
    PubMed     Text format     Abstract available


    February 2017
  34. ERNE P, Iglesias JF, Urban P, Eberli FR, et al
    Left bundle-branch block in patients with acute myocardial infarction: Presentation, treatment, and trends in outcome from 1997 to 2016 in routine clinical practice.
    Am Heart J. 2017;184:106-113.
    PubMed     Text format     Abstract available


    January 2017
  35. EGBE AC, Connolly HM, Niaz T, Yogeswaran V, et al
    Prevalence and outcome of thrombotic and embolic complications in adults after Fontan operation.
    Am Heart J. 2017;183:10-17.
    PubMed     Text format     Abstract available


  36. RIMAC G, Fearon WF, De Bruyne B, Ikeno F, et al
    Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis.
    Am Heart J. 2017;183:1-9.
    PubMed     Text format     Abstract available


    December 2016
  37. BABER U, Dangas G, Cohen DJ, Gibson CM, et al
    Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
    Am Heart J. 2016;182:125-134.
    PubMed     Text format     Abstract available


  38. GRODZINSKY A, Arnold SV, Wang TY, Sharma P, et al
    Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy.
    Am Heart J. 2016;182:111-118.
    PubMed     Text format     Abstract available


  39. HARRISON RW, Radhakrishnan V, Lam PS, Allocco DJ, et al
    Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts.
    Am Heart J. 2016;182:103-110.
    PubMed     Text format     Abstract available


  40. LEE JM, Cho DK, Hahn JY, Song YB, et al
    Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet The
    Am Heart J. 2016;182:1-8.
    PubMed     Text format     Abstract available


    November 2016
  41. YAKSH A, Kik C, Knops P, van Ettinger MJ, et al
    Early, de novo atrial fibrillation after coronary artery bypass grafting: Facts and features.
    Am Heart J. 2016;184:62-70.
    PubMed     Text format     Abstract available


  42. VEROUHIS D, Sorensson P, Gourine A, Henareh L, et al
    Effect of remote ischemic conditioning on infarct size in patients with anterior ST-elevation myocardial infarction.
    Am Heart J. 2016;181:66-73.
    PubMed     Text format     Abstract available


  43. PICCARO DE OLIVEIRA P, Gonzales V, Lopes RD, Schmidt MM, et al
    Serious infections among unselected patients with ST-elevation myocardial infarction treated with contemporary primary percutaneous coronary intervention.
    Am Heart J. 2016;181:52-59.
    PubMed     Text format     Abstract available


  44. DERY JP, Mehta SR, Fisher HN, Zhang X, et al
    Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTud
    Am Heart J. 2016;181:26-34.
    PubMed     Text format     Abstract available


  45. FERRI LA, Morici N, Grosseto D, Tortorella G, et al
    A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
    Am Heart J. 2016;181:101-106.
    PubMed     Text format     Abstract available


    October 2016
  46. AGARWAL SK, Kasula S, Almomani A, Hacioglu Y, et al
    Clinical and angiographic predictors of persistently ischemic fractional flow reserve after percutaneous revascularization.
    Am Heart J. 2016;184:10-16.
    PubMed     Text format     Abstract available


  47. SRA S, Tan MK, Mehta SR, Fisher HN, et al
    Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy.
    Am Heart J. 2016;180:82-9.
    PubMed     Text format     Abstract available


  48. KONTOS MC, Wang TY, Chen AY, Bates ER, et al
    The effect of high-risk ST elevation myocardial infarction transfer patients on risk-adjusted in-hospital mortality: A report from the American Heart Association Mission: Lifeline program.
    Am Heart J. 2016;180:74-81.
    PubMed     Text format     Abstract available


  49. LEMKES JS, Janssens GN, Straaten HM, Elbers PW, et al
    Coronary angiography after cardiac arrest: Rationale and design of the COACT trial.
    Am Heart J. 2016;180:39-45.
    PubMed     Text format     Abstract available


    September 2016
  50. MCNEELY C, Markwell S, Vassileva CM
    Readmission after inpatient percutaneous coronary intervention in the Medicare population from 2000 to 2012.
    Am Heart J. 2016;179:195-203.
    PubMed     Text format     Abstract available


  51. CHANG M, Ahn JM, Kim N, Lee PH, et al
    Complete versus incomplete revascularization in patients with multivessel coronary artery disease treated with drug-eluting stents.
    Am Heart J. 2016;179:157-65.
    PubMed     Text format     Abstract available


  52. DE WAHA A, Sandner S, von Scheidt M, Boening A, et al
    A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Inve
    Am Heart J. 2016;179:69-76.
    PubMed     Text format     Abstract available


  53. TANGUTURI VK, Wasfy JH
    Hospital readmissions after percutaneous coronary intervention aredeclining, but caution ahead is needed.
    Am Heart J. 2016;179:192-4.
    PubMed     Text format    


    August 2016
  54. DECKER C, Garavalia L, Garavalia B, Gialde E, et al
    Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention.
    Am Heart J. 2016;178:190-7.
    PubMed     Text format     Abstract available


  55. HARRISON RW, Simon D, Miller AL, de Lemos JA, et al
    Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;178:95-101.
    PubMed     Text format     Abstract available


  56. CAMARO C, Damen SA, Brouwer MA, Kedhi E, et al
    Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
    Am Heart J. 2016;178:37-44.
    PubMed     Text format     Abstract available


  57. RAO C, Du J, Li X, Li J, et al
    Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Se
    Am Heart J. 2016;178:9-18.
    PubMed     Text format     Abstract available


  58. ROTHBERG MB, Martinez KA
    Risky business: Personalizing the approach to percutaneous coronary intervention.
    Am Heart J. 2016;178:185-7.
    PubMed     Text format    


    July 2016
  59. DAYOUB EJ, Nallamothu BK
    Geographic access to transcatheter aortic valve replacement relative to other invasive cardiac services: A statewide analysis.
    Am Heart J. 2016;177:163-70.
    PubMed     Text format     Abstract available


  60. TING R, Tejpal A, Finken L, Fisher M, et al
    Repatriation to referral hospital after reperfusion of STEMI patients transferred for primary percutaneous coronary intervention: Insights of a Canadian regional STEMI care system.
    Am Heart J. 2016;177:145-52.
    PubMed     Text format     Abstract available


  61. NDREPEPA G, Iijima R, Kufner S, Braun S, et al
    Association of progression or regression of coronary artery atherosclerosis with long-term prognosis.
    Am Heart J. 2016;177:9-16.
    PubMed     Text format     Abstract available


  62. SHIMADA YJ, Bansilal S, Wiviott SD, Becker RC, et al
    Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
    Am Heart J. 2016;177:1-8.
    PubMed     Text format     Abstract available


    June 2016
  63. GRIMFJARD P, Erlinge D, Koul S, Lagerqvist B, et al
    Low real-world early stent thrombosis rates in ST-elevation myocardial infarction patients and the use of bivalirudin, heparin alone or glycoprotein IIb/IIIa inhibitor treatment: A nationwide Swedish registry report.
    Am Heart J. 2016;176:78-82.
    PubMed     Text format     Abstract available


  64. DE LUCA L, Capranzano P, Patti G, Parodi G, et al
    Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.
    Am Heart J. 2016;176:44-52.
    PubMed     Text format     Abstract available


  65. VAN DER HEIJDEN LC, Kok MM, Danse PW, Schramm AR, et al
    Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial.
    Am Heart J. 2016;176:28-35.
    PubMed     Text format     Abstract available


  66. ANDERSON LL, Dai D, Miller AL, Roe MT, et al
    Percutaneous coronary intervention for older adults who present with syncope and coronary artery disease? Insights from the National Cardiovascular Data Registry.
    Am Heart J. 2016;176:1-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vascular Surgery is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: